CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adverum Biotechnologies Inc   (NASDAQ: ADVM)


Adverum Biotechnologies Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adverum Biotechnologies Inc's ROI in the third quarter of 2025?
Adverum Biotechnologies Inc recorded a cumulative net loss of $-204 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -296.28%.

Within the Healthcare sector 741 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3732 to 4262.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Investment Change TTM -43.23 % -23.32 % -3.31 % 13.26 % -6.28 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 28 65 113 71 108
Return On Investment (TTM) -296.28 % -212.13 % -158.83 % -125.37 % -93.58 %
ADVM's Overall Ranking # 4262 # 3732 # 3512 # 0 # 3574
Seq. Investment Change TTM -22.61 % -16.91 % -10.64 % -1.19 % 4.52 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -204 -189 -170 -151 -114

ADVM Company Profile >> Back to ADVM Roi Comparisons >> See Annual ADVM Return On Investment



Return On Investment ADVM's Ranking
Within: No.
Industry # 118
Sector # 742
Overall # 4262

Return On Investment Statistics
High Average Low
26.98 %
-38.14 %
-132.74 %
(Dec 31 2014)   (Sep 30 2025)



  News about Adverum Biotechnologies Inc Return on Investment ROI

Adverum Biotechnologies Advances Towards Pivotal Phase 3 Trial Completion for Ixo-vec in Wet AMD Treatment

September 22, 2025

In an important development for ocular gene therapy, Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has announced the imminent completion of patient screening for its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec, a groundbreaking therapy for wet age-related macular degeneration (wet AMD). This announcement, made on September 22, 2025, highlights the company s commitment to innovative treatments aimed at preserving vision in patients suffering from this debilitating condition.The ARTEMIS trial, which commenced earlier in 2025, is a critical step in assessing the efficacy and safety of Ixo-vec, Adverum’s novel gene therapy designed for intravitreal administration. Wet AMD is a leading cause of vision loss among older adults, characterized by the abnormal growth of blood vessels in the retina, leading to swelling and damage. Current treatment modalities often require frequent injections, a burden that affects patient compliance and quality of life. Adverum aims to offer a transformative solution with Ixo-vec, envisioned as a “One And Done™” treatment approach that may provide long-lasting results with a single intervention.

Adverum Biotechnologies Faces Financial Struggles as Latest Financing Raises Questions

February 5, 2024

Adverum Biotechnologies Financing Raises Questions Amidst Substantial Losses
In recent news, Adverum Biotechnologies Inc, a leading biotech company, has announced a private placement financing of $127.5 million. The financing initiative was led by TCGX, with participation from both new and existing investors, including notable firms such as 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners, Vivo Capital, and two large investment management firms.
While the funding appears to be a positive development for Adverum, deeper analysis reveals concerning financial indicators. According to the company s financial statements, Adverum Biotechnologies Inc recorded a cumulative net loss of $-126 million during the 12 months ending in the third quarter of 2023. This substantial loss translates into a negative return on investment (ROI) of -87.91%.





Financial Statements
Adverum Biotechnologies Inc's III. Quarter Investments $ 28 Millions ADVM's Balance sheet
Adverum Biotechnologies Inc's III. Quarter Income $ -48 Millions Quarterly ADVM's Income Statement
ADVM's Income by Division See ADVM's Income by Division


ADVM Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 71 83 183 317 440
Y / Y Investment Growth -15.05 % -54.28 % -42.46 % -27.83 % 151.09 %
Net Income in Millions -131 -117 -155 -146 -118
Y / Y Net Income Growth - - - - -
Annual Return On Investment -184.65 % -140.37 % -84.65 % -45.87 % -26.73 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADVM's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADVM's Competitors
Subscribers only: Roi for Adverum Biotechnologies Inc's Suppliers
Subscribers only: Return On Investment for ADVM's Customers

Other Ratios
ADVM's Roa ADVM's Inventory Turnover Ratio ADVM's Growth Rates ADVM's Dividend Statistics
ADVM's Profitability Ratios ADVM's Asset Turnover Ratio ADVM's Dividend Growth
ADVM's Roe ADVM's Valuation Ratios ADVM's Financial Strength Ratios ADVM's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI

Date modified: 2026-08-29T17:23:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.